HBM Holdings Limited (HKG:2142)

Market Cap	6.27B
Revenue (ttm)	295.94M
Net Income (ttm)	21.58M
Shares Out	793.22M
EPS (ttm)	0.03
PE Ratio	281.62
Forward PE	12.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,076,000
Average Volume	8,063,966
Open	7.82
Previous Close	7.83
Day's Range	7.57 - 7.95
52-Week Range	1.06 - 10.00
Beta	1.72
RSI	39.62
Earnings Date	Aug 28, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD